People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Biotech / Pharma, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cornovus Pharmaceuticals Inc. | — | Biotech / Pharma | Seed | $3.1M | $3.0M | 2024 |
| Natural Polymer Devices, Inc. | — | Other Health Care | Pre-Seed | $150K | $4.6M | 2014 |
R. Mark Van Allen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside R. Mark Van Allen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Wagner | 1 | 13 |
| Timothy Shannon | 1 | 9 |
| Glenn Mattes | 1 | 1 |
| Bruce Liang | 1 | 1 |
| Raymond Neag | 1 | 1 |
| Margaret Mark Cartiera | 1 | 1 |
| Cato Mark Laurencin | 1 | 1 |
| Robert Mark Van Allen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.